INOOLAB Covid-19 FluoBolt™-DUO SN Antibody Test
The test in your pharmacy with laboratory quality and medical diagnosis.
The emergence of increasing numbers of infectious variants and waning immunity following infection or vaccination create the ongoing need for SARS-CoV-2 antibody measurements. The higher the antibody level, the greater the protection against infection. But not everyone can or wants to be vaccinated. In addition, there are a large number of clients who do not know whether the vaccine is actually working, such as patients with a diagnosis of cancer or immunocompromised individuals. The question of whether and how many antibodies were formed after a natural infection often remains unanswered. For these target groups, the antibody status and its development are relevant.
For this reason, in cooperation with Fianostics GmbH from Wiener Neustadt, Lower Austria, the INOOLAB Covid-19 FluoBolt™-DUO SN Antibody Test with laboratory results has been developed.
So you want to know your
Covid-19 Antibody Status?
Then this test is the right choice!
Dual Antibody test with laboratory results
The highly sensitive patented FluoBolt™ technology allows the simultaneous, i. e. dual quantitative detection of spike proteins (S1-RBD) and nucleocapsid (NC) antibodies against SARS-CoV-2 and is therefore used to assess the immune status after infection and/or vaccination. The results indicate whether a vaccination against SARS-CoV-2 has worked or whether a symptomless infection has been experienced.
The introductory price of the entire test kit is
This includes the collection of the sample in your pharmacy, the evaluation of the sample in the laboratory and the reporting by a laboratory physician.
The INOOLAB Covid-19 FluoBolt™-DUO SN Antibody Test measures the presence of S1-RBD antibodies (spike protein) and nucleocapsid antibodies.
The measurement results are given in µg/ml, thus indicating the concentration of antibodies in the blood.
In the laboratory report, the laboratory value is interpreted by a specialist in laboratory medicine.
The INOOLAB Covid-19 FluoBolt™-DUO SN Antibody Test is easily accessible to all individuals. The test is suitable for anyone who wants to check their COVID-19 antibody status and avoid venous blood sampling at the doctor's office. Moreover, it does not matter whether these persons have been vaccinated or have recovered (without symptoms), because the antibody test indicates in which way persons have formed antibodies or not. In addition, individuals with this testing will receive a laboratory medical report.
People who want to find out how many antibodies they have formed as a result of vaccination or (asymptomatic) infection. In some cases, the novel coronavirus causes only mild flu-like symptoms or even no symptoms at all. That is why many people are not sure whether they might not already have had the virus in them.
If you just have the symptoms of flu or cold, the antibody test is rather not worthwhile - at an early stage of the disease, the antibodies can not always be detected. If you want to find out whether you are acutely suffering from an infection, a PCR test that detects the virus in a DNA sample (saliva) is more useful.
The INOOLAB Covid-19 FluoBolt™-DUO SN Antibody Test takes place directly in the pharmacy and may only be performed by trained personnel.
Procedure of testing:
- Registration and appointment here.
- Allocate an automatically generated reference number by email (if you don't find it in your inbox, check the spam folder)
- Medically trained, expert personnel take the blood sample from the fingertip
- Payment is made at the pharmacy
- The sample is delivered to the laboratory by messengers
- The medically verified laboratory findings with explanation will be delivered directly via e-mail within a few days
INOOLAB - Innovative Blood Droplet Diagnostics was created in cooperation between Virinnox GmbH and Fianostics GmbH in Wiener Neustadt. INOOLAB offers
- Appointment management with simple web application
- Laboratory findings, medically verified, via e-mail directly to the customer
- Registration via QR code on site
- Blood drop collection
If pathogens such as viruses enter your body, the immune system works at full speed to fight them. Among other things, antibodies are produced in the process.
These antibodies are directed at very specific pathogens. Specific antibodies recognize a particular virus or bacterium, bind to the pathogen and allow immune cells to attack it.
Once your immune system has produced the antibodies, they remain in the body for a long time. How long depends on the class of antibodies. The IgG antibodies, for example, are active in combating viruses in some cases for years to come. As long as they are in the body, they can render the same virus harmless when they encounter it again. If this is the case, you are virtually immune to the pathogen - this is called immunization/immunity.
The S1-RBD antibody indicates whether antibodies have been produced in the human body as a result of vaccination and/or a covid-19 infection. Although no defined threshold for safe protection against infection has been defined to date, studies show that a high S1-RBD antibody level correlates with a low probability of infection.
The presence of nucleocapsid (NC) antibodies provides information as to whether one may have been infected with the virus even if asymptomatic. However, nucleocapsid antibodies do not protect against infection! After infection without symptoms, there is some increased likelihood of belonging to a group of people who tend to have milder courses in the currently known SARS-CoV-2 mutants.
If both S1-RBD antibody and NC antibody were detected, you most likely already had COVID-19 infection.
If neither S1-RBD antibodies nor NC antibodies were detected, this indicates that you have neither undergone an infection nor that the necessary immune protection has been built up by a possible vaccination.
SARS-CoV-2 is the scientific name for the novel coronavirus. The acronym stands for Severe Acute Respiratory Syndrome Coronavirus 2.
COVID-19 in turn stands for the disease that the virus causes. It is the abbreviation for Coronavirus-Disease-2019, which means Coronavirus-Disease-2019. The year refers to the first outbreak of the disease in China in December 2019. People of all ages can get the disease COVID-19. It occurs less frequently in children under 15 years of age, but has also occurred in infants. Severe and potentially dangerous courses mainly affect the elderly and people with pre-existing conditions (e.g., cancer, cardiovascular disease, diabetes, lung disease, asthma).
Mild or moderate courses occur in about 80 percent of those affected. In this case, symptoms include (usually dry) cough, fever and sometimes cold, up to mild pneumonia.
Some affected people also feel no symptoms at all, but are still contagious, they have so-called silent infections.
Meanwhile, studies also indicate that loss of sense of smell and taste may be a sign of coronavirus.
In severe courses, there is severe pneumonia with breathing difficulties and shortness of breath up to life-threatening lung and organ failure.
Other symptoms, which are less common but have also been reported, are, according to the Robert Koch Institute:
- Sore throat and headache and aching limbs
- Lack of appetite and weight loss
- Skin rashes
- Nausea, abdominal pain, vomiting and diarrhea
Sensitivity and specificity are statistical measures. They help in the evaluation of binary classification tests (tests with only 2 possible results).
Sensitivity measures the percentage of true positives that are correctly identified as such (e.g., the percentage of sick people that are correctly identified as such).
Specificity measures the proportion of true negatives that are correctly identified as such (e.g., the proportion of healthy people correctly identified as not ill).